Key terms

About VYGR

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VYGR news

Mar 19 9:53am ET Snowflake, MongoDB downgraded to Sell: Wall Street’s top analyst calls Mar 19 6:17am ET Voyager Therapeutics: A Buy Rating on Breakthrough CNS Gene Therapy Innovations and Strategic Growth Potential Mar 19 6:05am ET Voyager Therapeutics initiated with a Buy at H.C. Wainwright Mar 13 7:19am ET Voyager Therapeutics appoints Toby Ferguson as CMO Mar 06 5:15pm ET Voyager Therapeutics: A Strong Buy on CNS Gene Therapy Advances and Strategic Partnerships Mar 06 5:05pm ET Voyager Therapeutics initiated with a Buy at Citi Mar 05 7:25am ET Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst Mar 01 7:48am ET Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR) Mar 01 4:58am ET Voyager Therapeutics Buy Rating Affirmed Amid Strong Pipeline and Financial Health Mar 01 1:18am ET Voyager Therapeutics’ Promising Outlook in Gene Therapy: A Strong Buy Recommendation Feb 29 8:02am ET Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL) Feb 28 6:10pm ET Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Warby Parker (WRBY) Feb 26 7:16am ET Voyager Therapeutics reports selection of gene therapy development candidate Feb 20 7:06am ET Voyager Therapeutics reports preclinical activity on tau silencing gene therapy Jan 11 7:55am ET Oppenheimer Keeps Their Buy Rating on Voyager Therapeutics (VYGR) Jan 10 5:43am ET Voyager Therapeutics: A Strong Buy on Technological Superiority and Strategic Financial Health Jan 05 11:01am ET Biotech Alert: Searches spiking for these stocks today Jan 04 10:59pm ET Voyager Therapeutics 7.778M share Spot Secondary priced at $9.00 Jan 04 8:50pm ET Voyager Therapeutics prices $100M offering at $9 per share, Bloomberg says Jan 04 4:37pm ET Voyager Therapeutics $100M Spot Secondary; price range $9.00-$9.50 Jan 04 4:16pm ET Voyager Therapeutics announces $100M common stock offering Jan 04 11:13am ET Biotech Alert: Searches spiking for these stocks today Jan 04 6:48am ET Voyager Therapeutics price target raised to $18 from $16 at Oppenheimer Jan 03 6:43am ET Voyager Therapeutics price target raised to $18 from $15 at Baird Jan 02 1:19pm ET Wells Fargo upgrades Voyager on ‘highly validating’ Novartis deal Jan 02 1:12pm ET Wells Fargo upgrades Novartis on ‘highly validating’ Novartis deal Jan 02 1:05pm ET Voyager Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo Jan 02 8:08am ET M & A News: Voyager (NASDAQ:VYGR) Skyrockets on ~$1.3B Licensing Deal with Novartis (NYSE:NVS) Jan 02 7:02am ET Voyager Therapeutics enters capsid license agreement, collab with Novartis

No recent news articles are available for VYGR

No recent press releases are available for VYGR

VYGR Financials

1-year income & revenue

Key terms

VYGR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VYGR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms